NextGen Sciences Announces Commercial Alliance with Paragon Bioservices, Inc
CAMBRIDGESHIRE, England, Jan. 7, 2008 - NextGen Sciences, a wholly owned subsidiary of NextGen Group plc, the AIM-listed company, and a leading provider of gene-to-protein products and services, has announced a Commercial Alliance with Paragon Bioservices, Inc., (Baltimore, MD) a leading provider of contract research and manufacturing services in support of developing biologics. The Alliance expands the portfolio of both companies with the ability to offer existing and future customers an integrated offering including molecular biology, protein production, proteomics, functional assay development, biomarker discovery and monitoring.
This alliance extends NextGen Sciences' commitment to expand their fee for service offering in strategic partnerships in addition to adding new capabilities in house such as the protein biomarker monitoring services which was announced in November 2007. NextGen Sciences and Paragon Bioservices have agreed to co-market each others fee for service offerings to the market which now allows client companies to choose a one stop shop for their entire gene to protein needs.
Commenting on the Alliance, Dr Mike Pisano, CEO of NextGen Sciences, said: "We are delighted to be able to work more formally with the team at Paragon. I have known them for over the past five years and respect their excellent service record in the industry. They have great credibility in the market and together with the unique capabilities of NextGen Sciences, we believe that we have the broadest and most exciting range of products and services available in the gene to protein arena to take to our existing and potential new customers. Already the customers of both companies are telling us that this is an exciting opportunity for them and look forward to working with the new alliance."
"We are very excited about the Alliance with NextGen Sciences. Their instrumentation and software in the molecular biology area and their expertise in protein biomarker discovery and monitoring fits around our protein production and functional assay services very nicely", commented Dr Marco Chacon, CEO of Paragon Bioservices. "Working with NextGen Sciences gives our customers a broad range of services to access from a single point of contact whether you have been a customer of NextGen Sciences or Paragon Bioservices in the past"
- ENDS -
Contact
NextGen Sciences
Grant Cameron
t: +44 (0)1480 420970
e: grant.cameron@nextgensciences.com grant.cameron@nextgensciences.com>
Paragon Bioservices
Frank Marchesani
t: +1 (800) 545.6569
e: FMarchesani@paragonbioservices.com FMarchesani@paragonbioservices.com>
College Hill
Ben Routley, Katie Odgaard
t: +44 (0)1260 296508/ +44 (0)20 7866 7858
Notes to Editors:
About NextGen Sciences
NextGen Group PLC (LSE:NGG) offers its customers a comprehensive range of enabling technologies, services and expertise to improve their chance of success in protein science research. Working in partnership with 18 of the top 20 pharmaceutical companies, the Company's products and services cover the gene to protein continuum. The Company has developed a wide range of leading automation platforms and integrated software systems that have been proven to enhance the productivity and efficiency of customers' research programs. The services range from gene synthesis to protein expression scale-up and purification, protein analytical services, protein biomarker discovery and monitoring.
The breadth of services has been enhanced through key strategic partnerships with Gene Oracle, Inc., for gene optimization and synthesis, and Paragon Bioservices, Inc., for protein expression scale up, cell culture, protein purification and functional cell assays.
Further details relating to NextGen Group PLC and its products can be found at www.nextgensciences.com <http://www.nextgensciences.com/>
About Paragon Bioservices
Paragon Bioservices is a contract research and manufacturing company that provides preclinical services including process development, cell banking, protein expression, protein purification, and functional assays. The company has been in business for over 15 years and served more than half of the top 20 pharmaceutical and biotechnology companies in the world. In 2008, the Company is expanding its capabilities into a state-of-the-art new facility. The cornerstone of the new capabilities is the offering of cGMP manufacturing of developing biologics, such as therapeutic proteins, monoclonal antibodies and candidate vaccines, intended for Phase I/II human clinical trials.
For information on Paragon Bioservices Inc, visit www.paragonbioservices.com <http://www.paragonbioservices.com/>
Kind regards
Katie Odgaard
T: +44(0)20 7866 7858
Please consider the environment before printing this email
Northbank Communications is now College Hill Life Sciences. From 26 November our London address is...
CollegeHill
Click here for our location <http://www.collegehill.com/lifesciences/contact.htm>
The Registry Royal Mint Court London EC3N 4QN
T +44(0)20 7457 2020 F +44(0)20 7866 7900 www.collegehill.com/lifesciences <http://www.collegehill.com/lifesciences>
Pharma Industry News Archive
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec
